Sign in Subscribe
AstraZeneca PLC

AstraZeneca's Potential Departure from the London Stock Exchange Sparks Concern

Strategic Insights

— 1 min read

AstraZeneca, Britain's most valuable public company, may be considering a move of its listing to the United States, a development that has raised concerns among government officials and industry experts. The company's plans to relocate its UK base from Cheshire to a new £1.1 billion global research and development facility in Cambridge have been a major investment in the country's life sciences sector. However, Chief Executive Sir Pascal Soriot has expressed frustration with the restrictive approval process for innovative medicines by the National Institute for Health and Care Excellence (NICE) and an internationally uncompetitive NHS industry sales rebate scheme.

Key Takeaways:

  • Lord Lamont of Lerwick, a former chancellor of the exchequer, warned that losing AstraZeneca from the London Stock Exchange would be a "devastating blow" to the UK's life sciences sector.
  • AstraZeneca, under the leadership of Sir Pascal Soriot, has transformed into Britain's most valuable public company, with a market value of £1.1 billion.
  • The company's potential departure has raised concerns about the restrictive approval process for innovative medicines by the National Institute for Health and Care Excellence (NICE) and an NHS industry sales rebate scheme.
  • The UK government is due to publish its life sciences sector plan, which is expected to address the concerns raised by Soriot and others in the industry.
  • The London Stock Exchange risks losing a valuable listing if AstraZeneca decides to move its listing to the United States.
  • Lord Livermore, the Treasury minister, agreed with Lord Lamont's assessment of the importance of investing in the life sciences sector and expressed a desire to see high-growth companies stay in the UK.
  • Baroness Neville-Rolfe described AstraZeneca's potential departure as a "real blow" to the £160 billion UK stock market.
  • AstraZeneca scrapped a £450 million investment in expanding its flu vaccines site at Speke, near Liverpool, after the government missed its deadline to commit support.

Statistics:

  • AstraZeneca's market value: £160 billion (The Times, January 2023)
  • AstraZeneca's investment in the new global research and development facility in Cambridge: £1.1 billion
  • The value of the UK's life sciences sector: £160 billion
  • The amount of funding allocated for the life sciences sector: None, as the government's plan has been delayed.

Sources:

  • Lord Lamont of Lerwick, speaking in parliament (January 2023)
  • The Times (January 2023)
  • Baroness Neville-Rolfe, a Conservative shadow Treasury minister (January 2023)
  • Lord Livermore, the Treasury minister (January 2023)

Read more